Skip to content

Price / book at other companies

Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
3.5×+0.3×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
+0.5×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
4.9×+3.8×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
3.1×0.0×
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
6.1×+2.6×
Cytokinetics logo
CytokineticsCYTK
58.5×

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.26B+124%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Calculated from Mineralys Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s price / book?
Mineralys Therapeutics, Inc. (MLYS) reported price / book of 3.5× in Q1 2026.
How has Mineralys Therapeutics, Inc.'s price / book changed year-over-year?
Mineralys Therapeutics, Inc.'s price / book increased by 19.8% year-over-year, from 2.9× to 3.5×.
What is the long-term trend for Mineralys Therapeutics, Inc.'s price / book?
Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s price / book has grown at a 76.2% compound annual growth rate (CAGR), from 1.4× to 4.4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.